DSM Sinochem wins patent infringement ruling against Sinopharm Weiqida

By Flora Southey

- Last updated on GMT


Related tags Patent application

The High Court of Delhi, India, has granted a permanent injunction against Sinopharm Weiqida Pharmaceutical for patent infringement of DSM Sinochem Pharmaceuticals’ enzyme-based antibiotic production IP.

Indian Patent Number 247,301 is owned by DSM Sinochem Pharmaceuticals (DSP), and relates to enzymatic processes used to manufacture amoxicillin trihydrate.

“DSP tested Weiqida’s amoxicillin trihydrate samples to reverse engineer the manufacturing process likely used in their production,” ​DSM director of branding and communication Alice Beijersbergen told in-PharmaTechnologist.

“Weiqida failed to substantively defend against our claims of infringement or provide evidence of the use of an alternative process,” ​she said.

The ruling prevents the manufacture, use, importation, offering of sale and sale of Weiqida’s amoxicillin trihydrate active pharmaceutical ingredient (API) in India.

The injunction also prohibits these activities for any drug product that utilises the API.

“By restricting the flow of the Weiqida API through India, we disrupt the supply chain of infringing API,” ​said Beijersbergen.

Enzymes for antibiotics

According to DSP, its patented technologies have green, enzymatic routes for the production of amoxicillin and other antibiotics.

“DSP is continuing to invest in this sustainable technology, so it is important that our investment is protected from infringement, especially in major pharmaceutical markets like India,” ​said Beijersbergen. 

“DSP is open to licensing its technology to third parties, but it cannot tolerate infringement,” ​she said.

DSP has also filed patent litigation​ against Weiqida in the Netherlands over the European equivalent of this patent.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more